buyWeak
Eli N. Glezer bought $100k of OMIC
Chief Scientific Officer at Singular Genomics Systems, Inc.. 50,000 shares at an average of $2.00, traded Dec 12, 2022, filed Dec 13, 2022.
Conviction score
25Value
$100k
50,000 shares
Holdings after
4,185,000
+1% from before
From 52-week low
-
no price yet
From 52-week high
-
no price yet
Score components
- +15RoleOfficer
- +10Trade size$100k at market
- 0Relative to holdingsHoldings up 1.2%
- 0Price contextNo price history yet
- 0ClusterNo other insider buying within 14 days
- 0Repeat buyingFirst buy in 90 days
- 0Track recordToo few past buys to judge (0 with prices)
What happened after comparable buys
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Rows in this filing
Every transaction in Form 4 0001209191-22-061046, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Dec 12, 2022 | POpen-market purchase Common Stock | +50,000 | $2.00 | $100k | 4,185,000 | Dec 13, 2022 |
Related signals
Other insiders at Singular Genomics Systems, Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 15Weak | OMICsell Singular Genomics Systems, Inc. | Andrew Spaventa Chief Executive Officer | $3,629 180 shares | -22% | |
| 20Weak | OMICsell Singular Genomics Systems, Inc. | Andrew Spaventa Chief Executive Officer | $16k 695 shares | -31% | |
| 48Moderate | OMICbuy Singular Genomics Systems, Inc. | Kevin Tang owner | $1.8M 122,416 shares | +49% | |
| 15Weak | OMICsell Singular Genomics Systems, Inc. | Andrew Spaventa Chief Executive Officer | $2,167 175 shares | -22% | |
| 32Weak | Singular Genomics Systems, Inc. | Eli N. Glezer Chief Scientific Officer | $86k 200,000 shares | +5% | |
| 40Moderate | Singular Genomics Systems, Inc. | Andrew Spaventa Chief Executive Officer | $50k 118,468 shares | +3% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.